Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-525P refers to a pseudogene of the U6 small nuclear RNA (snRNA) family. U6 snRNA is a highly conserved non-coding RNA component of the spliceosome, essential for catalyzing the excision of introns from pre-mRNA during pre-mRNA splicing in the nucleus of eukaryotes[1][3]. However, RNU6-525P is annotated as a pseudogene: a DNA sequence similar to a functional gene but typically lacking the ability to encode a functional RNA or protein. Many pseudogenes, including those of U6, exist in the human genome as relics or duplicated segments and do not participate in canonical biological processes. Some pseudogenes can be transcribed and may play regulatory roles as non-coding RNAs, but there is no specific evidence for RNU6-525P functioning as a receptor, enzyme, or other pharmacological target[4]. Therefore, it is not a recognized therapeutic target. Key information: - This entry is not a conventional therapeutic target, as it is a pseudogene. - No evidence suggests it produces a functional RNA or protein or plays a direct role in disease, drug action, or as a biomarker. - The name and function refer specifically to a non-functional derivative of the canonical U6 snRNA gene. - Many similar U6 pseudogenes exist in the genome; their roles are typically non-coding and non-enzymatic[1][4]. Is there something wrong with this target? - Yes: It is not a targetable molecule in the traditional sense (not a receptor, enzyme, or transporter). - There is no established structure-function-disease mechanism or druggability. - Functional data required for most structured entries is missing or not applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 525, pseudogene (RNU6-525P).